Form 8-K - Current report:
SEC Accession No. 0001558370-22-017582
Filing Date
2022-11-14
Accepted
2022-11-14 07:46:22
Documents
14
Period of Report
2022-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tmb-20221114x8k.htm   iXBRL 8-K 42011
2 EX-99.1 tmb-20221114xex99d1.htm EX-99.1 96985
3 GRAPHIC tmb-20221114xex99d1001.jpg GRAPHIC 5633
  Complete submission text file 0001558370-22-017582.txt   281819

Data Files

Seq Description Document Type Size
4 EX-101.SCH tmb-20221114.xsd EX-101.SCH 3128
5 EX-101.LAB tmb-20221114_lab.xml EX-101.LAB 16582
6 EX-101.PRE tmb-20221114_pre.xml EX-101.PRE 11189
8 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20221114x8k_htm.xml XML 5090
Mailing Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451
Business Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40544 | Film No.: 221380336
SIC: 2834 Pharmaceutical Preparations